{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:33:44Z","timestamp":1773416024398,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s10384-025-01232-0","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T23:03:15Z","timestamp":1750460595000},"page":"529-535","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Increased macular atrophy area with photodynamic therapy over intravitreal aflibercept at 2-year follow-up of pachychoroid neovasculopathy"],"prefix":"10.1007","volume":"69","author":[{"given":"Hirokazu","family":"Kojima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieko","family":"Shiragami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2686-6980","authenticated-orcid":false,"given":"Ayana","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Osaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aoi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Suzuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"key":"1232_CR1","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","volume":"5","author":"SR Flaxman","year":"2017","unstructured":"Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e1221-34.","journal-title":"Lancet Glob Health"},{"key":"1232_CR2","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1097\/IAE.0b013e3182953df4","volume":"33","author":"DJ Warrow","year":"2013","unstructured":"Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy. Retina. 2013;33:1659\u201372.","journal-title":"Retina"},{"key":"1232_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000000331","volume":"35","author":"CE Pang","year":"2015","unstructured":"Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina. 2015;35:1\u20139.","journal-title":"Retina"},{"key":"1232_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","volume":"33","author":"CMG Cheung","year":"2019","unstructured":"Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB. Pachychoroid disease. Eye (Lond). 2019;33:14\u201333.","journal-title":"Eye (Lond)"},{"key":"1232_CR5","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1038\/s41598-019-38504-y","volume":"9","author":"BJ Jung","year":"2019","unstructured":"Jung BJ, Kim JY, Lee JH, Baek J, Lee K, Lee WK. Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy. Sci Rep. 2019;9:2055.","journal-title":"Sci Rep"},{"key":"1232_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10384-020-00722-7","volume":"64","author":"H Matsumoto","year":"2020","unstructured":"Matsumoto H, Mukai R, Kikuchi Y, Morimoto M, Akiyama H. One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions. Jpn J Ophthalmol. 2020;64:203\u20139.","journal-title":"Jpn J Ophthalmol"},{"key":"1232_CR7","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1007\/s10792-020-01522-1","volume":"40","author":"F Sartini","year":"2020","unstructured":"Sartini F, Figus M, Casini G, Nardi M, Posarelli C. Pachychoroid neovasculopathy: a type-1 choroidal neovascularization belonging to the pachychoroid spectrum-pathogenesis, imaging and available treatment options. Int Ophthalmol. 2020;40:3577\u201389.","journal-title":"Int Ophthalmol"},{"key":"1232_CR8","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1038\/s41433-021-01418-z","volume":"35","author":"T Hikichi","year":"2021","unstructured":"Hikichi T, Kubo N, Yamauchi M. One-year comparison of anti-vascular endothelial growth factor and half-dose photodynamic therapies for pachychoroid neovasculopathy. Eye (Lond). 2021;35:3367\u201375.","journal-title":"Eye (Lond)"},{"key":"1232_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171\u201385.","journal-title":"Angiogenesis"},{"key":"1232_CR10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ajo.2009.09.020","volume":"149","author":"A Yamashita","year":"2010","unstructured":"Yamashita A, Shiraga F, Shiragami C, Ono A, Tenkumo K. One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2010;149:465-71.e1.","journal-title":"Am J Ophthalmol"},{"key":"1232_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ajo.2012.06.027","volume":"155","author":"A Yamashita","year":"2013","unstructured":"Yamashita A, Shiraga F, Shiragami C, Shirakata Y, Fujiwara A. Two-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013;155:96-102.e1.","journal-title":"Am J Ophthalmol"},{"key":"1232_CR12","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1111\/aos.12482","volume":"92","author":"J Ma","year":"2014","unstructured":"Ma J, Meng N, Xu X, Zhou F, Qu Y. System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. Acta Ophthalmol. 2014;92:e594-601.","journal-title":"Acta Ophthalmol"},{"key":"1232_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41433-020-01265-4","volume":"35","author":"X Zhang","year":"2021","unstructured":"Zhang X, Sivaprasad S. Drusen and pachydrusen: the definition, pathogenesis, and clinical significance. Eye (Lond). 2021;35:121\u201333.","journal-title":"Eye (Lond)"},{"key":"1232_CR14","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/IAE.0000000000001689","volume":"38","author":"RF Spaide","year":"2018","unstructured":"Spaide RF. Disease expression in nonexudative age-related macular degeneration varies with choroidal thickness. Retina. 2018;38:708\u201316.","journal-title":"Retina"},{"key":"1232_CR15","doi-asserted-by":"publisher","first-page":"12052","DOI":"10.1038\/s41598-021-91589-2","volume":"11","author":"J Yoon","year":"2021","unstructured":"Yoon J, Yoon W, Na SK, Lee J, Kim CG, Kim JW, et al. Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy. Sci Rep. 2021;11:12052.","journal-title":"Sci Rep"},{"key":"1232_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0039-6257(00)00158-2","volume":"45","author":"U Schmidt-Erfurth","year":"2000","unstructured":"Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Survey Ophthalmol. 2000;45:195\u2013214.","journal-title":"Survey Ophthalmol"},{"key":"1232_CR17","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s00417-002-0517-4","volume":"240","author":"U Schl\u00f6tzer-Schrehardt","year":"2002","unstructured":"Schl\u00f6tzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol. 2002;240:748\u201357.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1232_CR18","first-page":"830","volume":"43","author":"U Schmidt-Erfurth","year":"2002","unstructured":"Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci. 2002;43:830\u201341.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1232_CR19","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/IAE.0000000000001980","volume":"39","author":"Y Takasago","year":"2019","unstructured":"Takasago Y, Shiragami C, Kobayashi M, Osaka R, Ono A, Yamashita A, et al. Macular atrophy findings by optical coherence tomography angiography compared with fundus autofluorescnce in treated exudative age-related macular degeneration. Retina. 2019;39:296\u2013302.","journal-title":"Retina"},{"key":"1232_CR20","first-page":"615","volume":"7","author":"T Tsuchihashi","year":"2013","unstructured":"Tsuchihashi T, Mori K, Ueyama K, Yoneya S. Five-year results of photodynamic therapy with verteporfin for Japanese patients with neovascular age-related macular degeneration. Clin Ophthalmol. 2013;7:615\u201320.","journal-title":"Clin Ophthalmol"},{"key":"1232_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1167\/iovs.05-0354","volume":"47","author":"S Michels","year":"2006","unstructured":"Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol. 2006;47:371\u20136.","journal-title":"Invest Ophthalmol"},{"key":"1232_CR22","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.ophtha.2012.02.013","volume":"119","author":"JE Grunwald","year":"2012","unstructured":"Grunwald JE, Daniel E, Ying GS, Pistilli M, Maguire MG, Alexander J, et al. Photographic assessment of baseline fundus morphologic features in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2012;119:1634\u201341.","journal-title":"Ophthalmology"},{"key":"1232_CR23","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000520171","volume":"245","author":"A Foss","year":"2022","unstructured":"Foss A, Rotsos T, Empeslidis T, Chong V. Development of macular atrophy in patients with wet age-related macular degeneration receiving anti-VEGF treatment. Ophthalmologica. 2022;245:204\u201317.","journal-title":"Ophthalmologica"},{"key":"1232_CR24","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/s41433-022-02067-6","volume":"37","author":"K Kawai","year":"2023","unstructured":"Kawai K, Miyata M, Ooto S, Tamura H, Ueda-Arakawa N, Takahashi A, et al. Macular atrophy at 5 years after photodynamic therapy for polypoidal choroidal vasculopathy. Eye (Lond). 2023;37:1067\u201372.","journal-title":"Eye (Lond)"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01232-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01232-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01232-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T21:24:28Z","timestamp":1757193868000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01232-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1232"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01232-0","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H. Kojima, None; C. Shiragami, None; A. Yamashita, None; Y. Miyoshi, None; R. Osaka, None; A. Ono, None; K. Suzuma, None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}